Please Wait...

CXCL8/IL8 // C-X-C motif chemokine 8 / Interleukin 8

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

CXCL8 was the first characterized chemokine and was initially named IL-8. CXCL8, expressed by activated Th17 helper cells, attracts and activates neutrophils cells (Walz et al., 1987).

CXCL8 bind two different receptors: CXCR1 and CXCR2. CXCR1 is specific for CXCL8 and CXCR2 binds also CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 and CXCL7. Under physiological conditions, CXCL8 exists as monomers and dimers and both forms bind the receptors but the monomeric forms have a better ability to induce CXCR1 phosphorylation, desensitization and internalization (whereas both forms induce these actions for CXCR2). Dimerization of CXCL8 is then implicated in the regulation of inflammatory response (Nasser et al., 2009).

 

CXCL8-IL8 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum.

 

Nasser, M.W., Raghuwanshi, S.K., Grant, D.J., Jala, V.R., Rajarathnam, K., and Richardson, R.M. (2009). Differential Activation and Regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J. Immunol. Baltim. Md 1950 183, 3425–3432.

Walz, A., Peveri, P., Aschauer, H., and Baggiolini, M. (1987). Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem. Biophys. Res. Commun. 149, 755–761.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen